Carolyn G. King

Prof. Dr. Carolyn G. King


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in Immunity
Verified
Journal Article
Closed access
CKCarolyn G. King
Carolyn G. King
SKSabrina Koehli
Sabrina Koehli
BHBarbara Hausmann
Barbara Hausmann
MSMathias Schmaler
Mathias Schmaler
DZDietmar Zehn
Dietmar Zehn
EPEd Palmer
Ed Palmer

8 January 2021 in Science Immunology
Verified
Journal Article
Closed access
PDF file
NSNivedya Swarnalekha
Nivedya Swarnalekha
DSDavid Schreiner
David Schreiner
LLLudivine C. Litzler
Ludivine C. Litzler
SISaadia Iftikhar
Saadia Iftikhar
DKDaniel Kirchmeier
Daniel Kirchmeier
CKCarolyn G. King
Carolyn G. King
Influenza is a deadly and costly infectious disease, even during flu seasons when an effective vaccine has been developed. To improve vaccines against respiratory viruses, a better understanding of the immune response at the site of infection is crucial. After influenza infection, clonally expanded T cells take up permanent residence in the lung, poised to rapidly respond to subsequent infection. Here, we characterized the dynamics and transcriptional regulation of lung-resident CD4+ T cells during influenza infection and identified a long-lived, Bcl6-dependent population that we have termed T resident helper (TRH) cells. TRH cells arise in the lung independently of lymph node T follicular helper cells but are dependent on B cells, with which they tightly colocalize in inducible bronchus-associated lymphoid tissue (iBALT). Deletion of Bcl6 in CD4+ T cells before heterotypic challenge infection resulted in redistribution of CD4+ T cells outside of iBALT areas and impaired local antibody production. These results highlight iBALT as a homeostatic niche for TRH cells and advocate for vaccination strategies that induce TRH cells in the lung.

29 September 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SKSimone Keck
Simone Keck
MSMathias Schmaler
Mathias Schmaler
SGStefan Ganter
Stefan Ganter
LWLena Wyss
Lena Wyss
SOSusanne Oberle
Susanne Oberle
CKCarolyn G. King
Carolyn G. King
Cumulative T-cell receptor signal strength and ensuing T-cell responses are affected by both antigen affinity and antigen dose. Here we examined the distinct contributions of these parameters to CD4 T-cell differentiation during infection. We found that high antigen affinity positively correlates with T helper (Th)1 differentiation at both high and low doses of antigen. In contrast, follicular helper T cell (TFH) effectors are generated after priming with high, intermediate, and low affinity ligand. Unexpectedly, memory T cells generated after priming with very low affinity antigen remain impaired in their ability to generate secondary Th1 effectors, despite being recalled with high affinity antigen. These data challenge the view that only strongly stimulated CD4 T cells are capable of differentiating into the TFH and memory T-cell compartments and reveal that differential strength of stimulation during primary T-cell activation imprints unique and long lasting T-cell differentiation programs.

13 March 2020 in Science Immunology
Verified
Journal Article
Closed access
PDF file
MKMarco Künzli
Marco Künzli
DSDavid Schreiner
David Schreiner
TPTamara C. Pereboom
Tamara C. Pereboom
NSNivedya Swarnalekha
Nivedya Swarnalekha
LLLudivine C. Litzler
Ludivine C. Litzler
CKCarolyn G. King
Carolyn G. King
T follicular helper (T fh ) cells are long lived and contribute to the maintenance of sustained humoral immunity.

16 October 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
DSDavid Schreiner
David Schreiner
CKCarolyn G. King
Carolyn G. King
During the last 10 years, a population of clonally expanded T cells that take up permanent residence in non-lymphoid tissues has been identified. The localization of these tissue resident memory (TRM) cells allows them to rapidly respond at the site of antigen exposure, making them an attractive therapeutic target for various immune interventions. Although most studies have focused on understanding the biology underlying CD8 TRMs, CD4 T cells actually far outnumber CD8 T cells in barrier tissues such as lung and skin. Depending on the immune context, CD4 TRM can contribute to immune protection, pathology, or tissue remodeling. Although the ability of CD4 T cells to differentiate into heterogeneous effector and memory subsets has been well-established, how this heterogeneity manifests within the TRM compartment and within different tissues is just beginning to be elucidated. In this review we will discuss our current understanding of how CD4 TRMs are generated and maintained as well as a potential role for CD4 TRM plasticity in mediating the balance between beneficial and pathogenic immune responses.

6 February 2023 in Current Opinion in Immunology
Verified
Journal Article
Open access
WNWadschma Naderi
Wadschma Naderi
DSDavid Schreiner
David Schreiner
CKCarolyn G. King
Carolyn G. King
Collaboration between T and B cells in secondary lymphoid organs is a crucial component of adaptive immunity, but lymphocytes also persist in other tissues. Recent studies have examined T-cell-B-cell interactions in nonlymphoid tissues such as the lung. CD4+ T- resident helper cells (TRH) remain in the lung after influenza infection and support both resident CD8 T cells and B cells. Multiple lung-resident B-cell subsets (B-resident memory (BRM)) that exhibit spatial and phenotypic diversity have also been described. Though not generated by all types of infection, inducible bronchus-associated lymphoid tissue offers a logical place for T and B cells to interact. Perturbations to BRM and TRH cells elicit effects specific to Immunoglobulin A (IgA) production, an antibody isotype with privileged access to mucosa. Understanding the interplay of lymphocytes in mucosal tissues, which can be insulated from systemic immune responses, may improve the design of future vaccines and therapies.